Understand the source comparison
What's the Difference Between KPV and LL-37 vs Oxytocin KLOW: Peptide Comparison
KPV (Lys-Pro-Val) NF-κB inhibition → reduced pro-inflammatory cytokine transcription Melanocortin receptors (indirect); intracellular pathway modulation Inflammatory bowel disease models, dermatitis, autoimmune inflammation 1–5 mg/kg subcutaneous or oral in ro
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- KPV (Lys-Pro-Val)
- NF-κB inhibition → reduced pro-inflammatory cytokine transcription
- Melanocortin receptors (indirect); intracellular pathway modulation
- Inflammatory bowel disease models, dermatitis, autoimmune inflammation
- 1–5 mg/kg subcutaneous or oral in rodent models
- Best choice for inflammation-dominant conditions without infection. Highly selective for activated inflammatory pathways
- LL-37
- Membrane disruption (antimicrobial); FPR2 binding (immune modulation)
- Bacterial lipid bilayers; formyl peptide receptor 2 (FPR2) on leukocytes
- Antimicrobial susceptibility testing, biofilm disruption, wound infection models
- 2–10 μg/mL in vitro; 5–20 mg/kg in vivo (rodent wound models)
- Required when microbial load is a research variable. Dual action makes it suitable for infected tissue models
- Oxytocin
- GPCR activation → intracellular calcium release and smooth muscle contraction or neurotransmitter modulation
- Oxytocin receptors (OXTR) in hypothalamus, uterus, mammary tissue, select CNS regions
- Social behavior studies, uterine contraction assays, lactation research, pair bonding models
- 0.1–1.0 IU/kg IV or intranasal (dose-dependent on species and endpoint)
- Exclusively for neuroendocrine or reproductive research. Extremely short half-life (1–6 min) limits sustained-effect studies
- KLOW (Wolverine)
- Multi-target: combines KPV anti-inflammatory, LL-37 antimicrobial, +/- oxytocin or other peptides
- Variable depending on formulation. Typically melanocortin, FPR2, OXTR, others
- Exploratory multi-system models (wound healing + infection, IBD + dysbiosis, immune-neuro studies)
- Varies by formulation. Typically 0.5–2 mL total volume delivering multiple peptides at vendor-specified ratios
- Useful for pilot studies requiring broad-spectrum activity. Poor choice for mechanistic work requiring single-pathway dose control